Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Retained Earnings (2022 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Retained Earnings for 4 consecutive years, with -$762.4 million as the latest value for Q4 2025.

  • Quarterly Retained Earnings fell 36.49% to -$762.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$762.4 million through Dec 2025, down 36.49% year-over-year, with the annual reading at -$762.4 million for FY2025, 36.49% down from the prior year.
  • Retained Earnings hit -$762.4 million in Q4 2025 for NewAmsterdam Pharma, down from -$687.5 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $4.4 million in Q4 2023 to a low of -$762.4 million in Q4 2025.
  • Historically, Retained Earnings has averaged -$317.7 million across 4 years, with a median of -$294.1 million in 2022.
  • Biggest five-year swings in Retained Earnings: soared 103.63% in 2023 and later tumbled 13625.51% in 2025.
  • Year by year, Retained Earnings stood at -$121.8 million in 2022, then skyrocketed by 103.63% to $4.4 million in 2023, then tumbled by 12731.64% to -$558.6 million in 2024, then plummeted by 36.49% to -$762.4 million in 2025.
  • Business Quant data shows Retained Earnings for NAMS at -$762.4 million in Q4 2025, -$687.5 million in Q3 2025, and $4.3 million in Q2 2025.